H3 K27M clinical trials at UCLA
1 research study open to eligible people
open to all eligible people
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Los Angeles, California and other locations
Our lead scientists for H3 K27M research studies include Phioanh Nghiemphu, MD.